FWM
TGTX icon

Focused Wealth Management’s TG Therapeutics TGTX Stock Holding History

Focused Wealth Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-47
Closed -$1K – 867
2020
Q2 		$1K Sell
47
-50
-52% -$805 ﹤0.01% 728
2020
Q1 		$1K Sell
97
-3,750
-97% -$47.4K ﹤0.01% 678
2019
Q4 		$43K Hold
3,847
– – 0.01% 331
2019
Q3 		$22K Buy
+3,847
New +$26.8K 0.01% 379

Other funds holding TGTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Focused Wealth Management's TGTX Position: Q3 2020 in Review

Focused Wealth Management sold out of TG Therapeutics (TGTX) in Q3 2020, closing a stake of 47 shares — an estimated $1K sold.

Focused Wealth Management first reported a position in TGTX in Q3 2019 and held it in 4 quarters. The position peaked at $43K in Q4 2019. 181 funds tracked by Wall St. Rank hold TGTX as of Q3 2020.

  • Focused Wealth Management reported no remaining TG Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Focused Wealth Management sold 47 TG Therapeutics shares in Q3 2020, an estimated $1K.
  • Focused Wealth Management first reported a position in TG Therapeutics in Q3 2019 and held it in 4 quarters.
  • Focused Wealth Management's TG Therapeutics position peaked at $43K in Q4 2019.
  • 181 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2020.

Based on Focused Wealth Management's 13F filing for Q3 2020, filed 19 Oct 2020.